Related references
Note: Only part of the references are listed.Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol
Tuukka Saarikoski et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Drug Interactions between Nine Antifungal Agents and Drugs Metabolized by Human Cytochromes P450
Toshiro Niwa et al.
CURRENT DRUG METABOLISM (2014)
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects
Sreeneeranj Kasichayanula et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications
Chris Stockmann et al.
CLINICAL PHARMACOKINETICS (2014)
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies
A. B. Ke et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Ritonavir Analogues as a Probe for Deciphering the Cytochrome P450 3A4 Inhibitory Mechanism
Irina F. Sevrioukova et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2014)
Liver Injury Associated With Ketoconazole: Review of the Published Evidence
H. Karl Greenblatt et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4
Brooke M. Rock et al.
MOLECULAR PHARMACOLOGY (2014)
Cytochrome P450 Inhibitory Properties of Common Efflux Transporter Inhibitors
Gunilla Englund et al.
DRUG METABOLISM AND DISPOSITION (2014)
Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers
Virginie Ancrenaz et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2013)
A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions
B. Halama et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin
Sara K. Quinney et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity
Ines Fuchs et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Concentration effect relationship of CYP3A inhibition by ritonavir in humans
Christine Eichbaum et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1
Christoph Markert et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail
Peter N. Morcos et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections
Jodi Lestner et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Pharmacokinetic and Pharmacodynamic Interaction of Nadolol With Itraconazole, Rifampicin and Grapefruit Juice in Healthy Volunteers
Shingen Misaka et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p-Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs
Ichiro Ieiri et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro
Eve-Irene Lepist et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Drug Interaction Studies With CYP3A Substrates: How Much Inhibitor Pre-exposure Is Needed?
David J. Greenblatt
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2012)
Risk Assessment of Mechanism-Based Inactivation in Drug-Drug Interactions
Yasushi Fujioka et al.
DRUG METABOLISM AND DISPOSITION (2012)
Complex Drug Interactions of the HIV Protease Inhibitors 3: Effect of Simultaneous or Staggered Dosing of Digoxin and Ritonavir, Nelfinavir, Rifampin, or Bupropion
Brian J. Kirby et al.
DRUG METABOLISM AND DISPOSITION (2012)
Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy
S. Katzenmaier et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir
Brian J. Kirby et al.
DRUG METABOLISM AND DISPOSITION (2011)
Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir
Brian J. Kirby et al.
DRUG METABOLISM AND DISPOSITION (2011)
Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity
Siamak Cyrus Khojasteh et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2011)
Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover
K. Rowland Yeo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren
Tuija Tapaninen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Mechanism of cytochrome P450-3A inhibition by ketoconazole
David J. Greenblatt et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2011)
Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data
I. Templeton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro
David J. Greenblatt et al.
XENOBIOTICA (2010)
Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
Lianhong Xu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase
David J. Greenblatt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Short-Term Clarithromycin Administration Impairs Clearance and Enhances Pharmacodynamic Effects of Trazodone but Not of Zolpidem
D. Farkas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Effects of Oral Posaconazole on the Pharmacokinetic Properties of Oral and Intravenous Midazolam: A Phase I, Randomized, Open-Label, Crossover Study in Healthy Volunteers
Gopal Krishna et al.
CLINICAL THERAPEUTICS (2009)
Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2009)
Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Effect of Different Durations of Ketoconazole Dosing on the Single-Dose Pharmacokinetics of Midazolam: Shortening the Paradigm
S. A. Stoch et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Effect of Saquinavir-Ritonavir on Cytochrome P450 3A4 Activity in Healthy Volunteers Using Midazolam as a Probe
Christophe Schmitt et al.
PHARMACOTHERAPY (2009)
The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers
Tomonori Tateishi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Interaction between midazolam and clarithromycin in the elderly
Sara K. Quinney et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities
E. D. Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients
C. Wyen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo
I. E. Templeton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome p450 3A4 and the role of therapeutic drug monitoring
Shu-Feng Zhou et al.
THERAPEUTIC DRUG MONITORING (2007)
Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: Implications for predicting clinical drug interactions
Vaishali Dixit et al.
DRUG METABOLISM AND DISPOSITION (2007)
Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans
Toshiaki Okudaira et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Time-dependent interaction between lopinavir/ritonavir and fexofenadine
Rolf P. G. van Heeswijk et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of Bupropion administered to human volunteers
LM Hesse et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Comparison of midazolam and simvastatin as cytochromc P450 3A probes
E Chung et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate
TM Polasek et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir
KE Culm-Merdek et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin
B Gurley et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Prediction of time-dependent CYP3A4 drug-drug interactions: Impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition
A Galetin et al.
DRUG METABOLISM AND DISPOSITION (2006)
Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers
RE Aarnoutse et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Cytochrome P450 enzymes mechanism based inhibitors: Common sub-structures and reactivity
E Fontana et al.
CURRENT DRUG METABOLISM (2005)
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions
A Galetin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Role of itraconazole metabolites in CYP3A4 inhibition
N Isoherranen et al.
DRUG METABOLISM AND DISPOSITION (2004)
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers
R Ding et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes
SR Penzak et al.
THERAPEUTIC DRUG MONITORING (2004)
Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity
CB Eap et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
SF Zhou et al.
CURRENT DRUG METABOLISM (2004)
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction
J Rengelshausen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes
K Ito et al.
DRUG METABOLISM AND DISPOSITION (2003)
Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone
YWF Lam et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors
TH Tran et al.
DRUG METABOLISM AND DISPOSITION (2002)
Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping
JI Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers
SR Penzak et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2002)
Coadministration of digoxin with itraconazole in renal transplant recipients
AS Mathis et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2001)
Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus
Y Khaliq et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole
LL von Moltke et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450
Y Sai et al.
XENOBIOTICA (2000)
Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance
K Venkatakrishnan et al.
CLINICAL PHARMACOKINETICS (2000)
Share Paper
